{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:01:26Z","timestamp":1790017286281,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,21]]},"DOI":"10.7759\/cureus.116657","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:11:05Z","timestamp":1790014265000},"source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes of Vancomycin and \u03b2-Lactam Antibiotics in Adults With Augmented Renal Clearance: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Mohammed","family":"Asiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mashail","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghaleb","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics9030036","article-title":"Augmented renal clearance in critical illness: an important consideration in drug dosing","volume":"9","author":"Mahmoud SH","year":"2017","unstructured":"Mahmoud SH, Shen C. Augmented renal clearance in critical illness: an important consideration in drug dosing. Pharmaceutics. 2017, 9:36. 10.3390\/pharmaceutics9030036","journal-title":"Pharmaceutics"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2165\/11318140-000000000-00000","article-title":"Augmented renal clearance: implications for antibacterial dosing in the critically ill","volume":"49","author":"Udy AA","year":"2010","unstructured":"Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010, 49:1-16. 10.2165\/11318140-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020445","article-title":"Prevalence and risk factors of augmented renal clearance: a systematic review and meta-analysis","volume":"14","author":"Hefny F","year":"2022","unstructured":"Hefny F, Stuart A, Kung JY, Mahmoud SH. Prevalence and risk factors of augmented renal clearance: a systematic review and meta-analysis. Pharmaceutics. 2022, 14:445. 10.3390\/pharmaceutics14020445","journal-title":"Pharmaceutics"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0636-7","article-title":"Augmented renal clearance in critically ill patients: a systematic review","volume":"57","author":"Bilbao-Meseguer I","year":"2018","unstructured":"Bilbao-Meseguer I, Rodr\u00edguez-Gasc\u00f3n A, Barrasa H, Isla A, Solin\u00eds M\u00c1. Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet. 2018, 57:1107-21. 10.1007\/s40262-018-0636-7","journal-title":"Clin Pharmacokinet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1653","article-title":"Implications of augmented renal clearance on drug dosing in critically ill patients: a focus on antibiotics","volume":"35","author":"Hobbs AL","year":"2015","unstructured":"Hobbs AL, Shea KM, Roberts KM, Daley MJ. Implications of augmented renal clearance on drug dosing in critically ill patients: a focus on antibiotics. Pharmacotherapy. 2015, 35:1063-75. 10.1002\/phar.1653","journal-title":"Pharmacotherapy"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-022-01569-1","article-title":"Augmented renal clearance in patients with acute ischemic stroke: a prospective observational study","volume":"38","author":"John G","year":"2023","unstructured":"John G, Heffner E, Carter T, Beckham R, Smith N. Augmented renal clearance in patients with acute ischemic stroke: a prospective observational study. Neurocrit Care. 2023, 38:35-40. 10.1007\/s12028-022-01569-1","journal-title":"Neurocrit Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-013-3088-4","article-title":"Clinical implications of antibiotic pharmacokinetic principles in the critically ill","volume":"39","author":"Udy AA","year":"2013","unstructured":"Udy AA, Roberts JA, Lipman J. Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med. 2013, 39:2070-82. 10.1007\/s00134-013-3088-4","journal-title":"Intensive Care Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts JA","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J, et al.. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014, 14:498-509. 10.1016\/S1473-3099(14)70036-2","journal-title":"Lancet Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2020-002477","article-title":"Predictive performance of reported vancomycin population pharmacokinetic model in patients with different renal function status, especially those with augmented renal clearance","volume":"29","author":"Yu YX","year":"2022","unstructured":"Yu YX, Lu J, Lu HD, et al.. Predictive performance of reported vancomycin population pharmacokinetic model in patients with different renal function status, especially those with augmented renal clearance. Eur J Hosp Pharm. 2022, 29:e6-14. 10.1136\/ejhpharm-2020-002477","journal-title":"Eur J Hosp Pharm"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha SG","year":"2021","unstructured":"Wicha SG, M\u00e4rtson AG, Nielsen EI, Koch BC, Friberg LE, Alffenaar JW, Minichmayr IK. From therapeutic drug monitoring to model-informed precision dosing for antibiotics. Clin Pharmacol Ther. 2021, 109:928-41. 10.1002\/cpt.2202","journal-title":"Clin Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak MJ","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, et al.. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020, 77:835-64. 10.1093\/ajhp\/zxaa036","journal-title":"Am J Health Syst Pharm"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000944","article-title":"Optimal practice for vancomycin therapeutic drug monitoring: position statement from the anti-infectives committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","volume":"44","author":"Reuter SE","year":"2022","unstructured":"Reuter SE, Stocker SL, Alffenaar JC, et al.. Optimal practice for vancomycin therapeutic drug monitoring: position statement from the anti-infectives committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2022, 44:121-32. 10.1097\/FTD.0000000000000944","journal-title":"Ther Drug Monit"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14030489","article-title":"Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"14","author":"Matsumoto K","year":"2022","unstructured":"Matsumoto K, Oda K, Shoji K, et al.. Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Pharmaceutics. 2022, 14:489. 10.3390\/pharmaceutics14030489","journal-title":"Pharmaceutics"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13082317","article-title":"The impact of augmented renal clearance on vancomycin pharmacokinetics and pharmacodynamics in critically ill patients","volume":"13","author":"Tesfamariam NS","year":"2024","unstructured":"Tesfamariam NS, Aboelezz A, Mahmoud SH. The impact of augmented renal clearance on vancomycin pharmacokinetics and pharmacodynamics in critically ill patients. J Clin Med. 2024, 13:2317. 10.3390\/jcm13082317","journal-title":"J Clin Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2013.03.003","article-title":"Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy","volume":"28","author":"Claus BO","year":"2013","unstructured":"Claus BO, Hoste EA, Colpaert K, Robays H, Decruyenaere J, De Waele JJ. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care. 2013, 28:695-700. 10.1016\/j.jcrc.2013.03.003","journal-title":"J Crit Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.11.013","article-title":"Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of \u03b2-lactams administered by continuous infusion: a prospective observational study","volume":"51","author":"Carri\u00e9 C","year":"2018","unstructured":"Carri\u00e9 C, Petit L, d'Houdain N, et al.. Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of \u03b2-lactams administered by continuous infusion: a prospective observational study. Int J Antimicrob Agents. 2018, 51:443-9. 10.1016\/j.ijantimicag.2017.11.013","journal-title":"Int J Antimicrob Agents"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106299","article-title":"Pharmacokinetics and pharmacodynamics of ceftolozane\/tazobactam in critically ill patients with augmented renal clearance","volume":"57","author":"Nicolau DP","year":"2021","unstructured":"Nicolau DP, De Waele J, Kuti JL, et al.. Pharmacokinetics and pharmacodynamics of ceftolozane\/tazobactam in critically ill patients with augmented renal clearance. Int J Antimicrob Agents. 2021, 57:106299. 10.1016\/j.ijantimicag.2021.106299","journal-title":"Int J Antimicrob Agents"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2018-001781","article-title":"Application of vancomycin in patients with augmented renal clearance","volume":"27","author":"Chu Y","year":"2020","unstructured":"Chu Y, Luo Y, Jiang M, Zhou B. Application of vancomycin in patients with augmented renal clearance. Eur J Hosp Pharm. 2020, 27:276-9. 10.1136\/ejhpharm-2018-001781","journal-title":"Eur J Hosp Pharm"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2019.06.016","article-title":"Population pharmacokinetics of vancomycin in Chinese patients with augmented renal clearance","volume":"13","author":"Chu Y","year":"2020","unstructured":"Chu Y, Luo Y, Ji S, Jiang M, Zhou B. Population pharmacokinetics of vancomycin in Chinese patients with augmented renal clearance. J Infect Public Health. 2020, 13:68-74. 10.1016\/j.jiph.2019.06.016","journal-title":"J Infect Public Health"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomized trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomized trials. BMJ. 2019, 366:I4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03773-5","article-title":"Ceftolozane\/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial","volume":"25","author":"Shorr AF","year":"2021","unstructured":"Shorr AF, Bruno CJ, Zhang Z, et al.. Ceftolozane\/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial. Crit Care. 2021, 25:354. 10.1186\/s13054-021-03773-5","journal-title":"Crit Care"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1041152","article-title":"Evaluation of vancomycin pharmacokinetics in patients with augmented renal clearances: a randomized clinical trial","volume":"13","author":"Sahraei Z","year":"2022","unstructured":"Sahraei Z, Saffaei A, Alavi Darazam I, et al.. Evaluation of vancomycin pharmacokinetics in patients with augmented renal clearances: a randomized clinical trial. Front Pharmacol. 2022, 13:1041152. 10.3389\/fphar.2022.1041152","journal-title":"Front Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-022-03291-5","article-title":"Investigation of pharmacokinetic and clinical outcomes of various meropenem regimens in patients with ventilator-associated pneumonia and augmented renal clearance","volume":"78","author":"Razzazzadeh S","year":"2022","unstructured":"Razzazzadeh S, Darazam IA, Hajiesmaeili M, Salamzadeh J, Mahboubi A, Sadeghnezhad E, Sahraei Z. Investigation of pharmacokinetic and clinical outcomes of various meropenem regimens in patients with ventilator-associated pneumonia and augmented renal clearance. Eur J Clin Pharmacol. 2022, 78:823-9. 10.1007\/s00228-022-03291-5","journal-title":"Eur J Clin Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.21037\/tau-20-1048","article-title":"A higher dose of vancomycin is needed in critically ill patients with augmented renal clearance","volume":"9","author":"He J","year":"2020","unstructured":"He J, Yang ZT, Qian X, Zhao B, Mao EQ, Chen EZ, Bian XL. A higher dose of vancomycin is needed in critically ill patients with augmented renal clearance. Transl Androl Urol. 2020, 9:2166-71. 10.21037\/tau-20-1048","journal-title":"Transl Androl Urol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020551","article-title":"Measuring creatinine clearance is the most accurate way for calculating the proper continuous infusion meropenem dose for empirical treatment of severe gram-negative infections among critically ill patients","volume":"15","author":"Troisi C","year":"2023","unstructured":"Troisi C, Cojutti PG, Rinaldi M, Laici C, Siniscalchi A, Viale P, Pea F. Measuring creatinine clearance is the most accurate way for calculating the proper continuous infusion meropenem dose for empirical treatment of severe gram-negative infections among critically ill patients. Pharmaceutics. 2023, 15:551. 10.3390\/pharmaceutics15020551","journal-title":"Pharmaceutics"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac261","article-title":"Imipenem\/cilastatin\/relebactam pharmacokinetics in critically ill patients with augmented renal clearance","volume":"77","author":"Fratoni AJ","year":"2022","unstructured":"Fratoni AJ, Mah JW, Nicolau DP, Kuti JL. Imipenem\/cilastatin\/relebactam pharmacokinetics in critically ill patients with augmented renal clearance. J Antimicrob Chemother. 2022, 77:2992-9. 10.1093\/jac\/dkac261","journal-title":"J Antimicrob Chemother"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2021.10.008","article-title":"Clinical applicability of urinary creatinine clearance for determining the initial dose of vancomycin in critically ill patients","volume":"28","author":"Mikami R","year":"2022","unstructured":"Mikami R, Imai S, Hayakawa M, Sugawara M, Takekuma Y. Clinical applicability of urinary creatinine clearance for determining the initial dose of vancomycin in critically ill patients. J Infect Chemother. 2022, 28:199-205. 10.1016\/j.jiac.2021.10.008","journal-title":"J Infect Chemother"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2021.09.017","article-title":"Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia","volume":"29","author":"Alsultan A","year":"2021","unstructured":"Alsultan A, Dasuqi SA, Aljamaan F, et al.. Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia. Saudi Pharm J. 2021, 29:1272-7. 10.1016\/j.jsps.2021.09.017","journal-title":"Saudi Pharm J"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.622948","article-title":"A regression model to predict augmented renal clearance in critically ill obstetric patients and effects on vancomycin treatment","volume":"12","author":"Tang L","year":"2021","unstructured":"Tang L, Ding XY, Duan LF, et al.. A regression model to predict augmented renal clearance in critically ill obstetric patients and effects on vancomycin treatment. Front Pharmacol. 2021, 12:622948. 10.3389\/fphar.2021.622948","journal-title":"Front Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520949076","article-title":"Effect of augmented renal clearance on the therapeutic drug monitoring of vancomycin in patients after neurosurgery","volume":"48","author":"Chen Y","year":"2020","unstructured":"Chen Y, Liu L, Zhu M. Effect of augmented renal clearance on the therapeutic drug monitoring of vancomycin in patients after neurosurgery. J Int Med Res. 2020, 48:300060520949076. 10.1177\/0300060520949076","journal-title":"J Int Med Res"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02432.x","article-title":"Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation","volume":"60","author":"Mulla H","year":"2005","unstructured":"Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol. 2005, 60:265-75. 10.1111\/j.1365-2125.2005.02432.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018.1440287","article-title":"Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters","volume":"14","author":"Smit C","year":"2018","unstructured":"Smit C, De Hoogd S, Br\u00fcggemann RJ, Knibbe CA. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxicol. 2018, 14:275-85. 10.1080\/17425255.2018.1440287","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00980-20","article-title":"Urinary creatinine clearance and pharmacokinetics studies: if we can measure it, why do we estimate it?","volume":"64","author":"Silva CM","year":"2020","unstructured":"Silva CM, Udy AA, Baptista JP. Urinary creatinine clearance and pharmacokinetics studies: if we can measure it, why do we estimate it?. Antimicrob Agents Chemother. 2020, 64:10.1128\/AAC.00980-20","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/532210-pharmacokinetic-pharmacodynamic-and-clinical-outcomes-of-vancomycin-and--lactam-antibiotics-in-adults-with-augmented-renal-clearance-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:11:06Z","timestamp":1790014266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/532210-pharmacokinetic-pharmacodynamic-and-clinical-outcomes-of-vancomycin-and--lactam-antibiotics-in-adults-with-augmented-renal-clearance-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.116657","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,21]]}}}